Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis

Aithal, Guruprasad P., Thomas, James A., Kaye, Philip V., Lawson, Adam, Ryder, Stephen D., Spendlove, Ian, Austin, Andrew S., Freeman, Jan G. +2 more·2008·Gastroenterology
DOI 10.1053/j.gastro.2008.06.047

Cited by (719)

Items 601–700 of 719

  1. Association of insulin resistance and non-alcoholic fatty liver disease
    Ekaterina Е. Mishina, Alexander Yur'evich Mayorov, Pavel Bogomolov, Ekaterina O. Liusina, Alexey O. Bueverov · 2021 · Diabetes Mellitus
  2. What proportion of people have a follow-up biopsy in randomized trials of treatments for non-alcoholic steatohepatitis?: A systematic review and meta-analysis
    Dimitrios A. Koutoukidis, Elizabeth M. Morris, John A. Henry, Yusra Shammoon, Matthew Zimmerman, Moscho Michalopoulou, Susan Ann Jebb, Paul N Aveyard · 2021 · PLoS ONE
  3. The Glycemic, Cardiovascular and Hepatic Outcomes of Pioglitazone Treatment: Evidence for Its Increased Use
    Mayer B. Davidson · 2020
  4. The role of pioglitazone in the fight against insulin resistance, atherosclerosis, cardiovascular disease, and non-alcoholic fatty liver disease
    Nina Alexandrovna Petunina, Гончарова Екатерина Валерьевна, И. А. Кузина, Л. В. Недосугова, Мартиросян Нарине Степановна, Тельнова Милена Эдуардовна · 2022 · Diabetes Mellitus
  5. Combination therapy in type 2 diabetes mellitus
    Muhammad A Abdul‐Ghani, Ralph Anthony DeFronzo, Roy Eldor · 2015 · Wiley eBooks
  6. Is vitamin e or ursodeoxycholic acid a valid treatment option for nonalcoholic fatty liver disease in 2016?
    M Beaton, Bandar Al-Judaibi · 2016 · Saudi Journal of Gastroenterology
  7. Breast cancer endocrine therapy exhausts adipocyte progenitors promoting weight gain and glucose intolerance
    Rebecca L. Scalzo, Rebecca M. Foright, Sara Hull, Leslie A. Knaub, Stevi Johnson-Murguia, Fotobari Kinanee, Jeffrey Kaplan, Benjamin Freije, Gregory Verzosa, Julie A. Houck et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
  8. Genomics-Informed Drug Repurposing Strategy Identifies Novel Therapeutic Targets for Metabolic Dysfunction-Associated Steatotic Liver Disease
    Hannah M. Seagle, Alexis T. Akerele, Joseph A. DeCorte, Jacklyn N. Hellwege, Joseph H. Breeyear, Jeewoo Kim, Michael G. Levin, Samuel Khodurksy, Adam Phillip Bress, Kyung Min Lee et al. · 2025 · medRxiv
  9. Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages
    Aquino, Jorge Benjamin · 2026 · Frontiers in Immunology
  10. Gastrointestinal Manifestations in Diabetes Mellitus and Management
    Arulprakash Sarangapani · 2024 · Springer eBooks
  11. Restoring Mitochondrial Homeostasis: Therapeutic Strategies for Metabolic Dysfunction-Associated Fatty Liver Disease
    J. Morgado, Ivo F. Machado, Anabela Pinto Rolo, Carlos M. Palmeira · 2026 · International Journal of Molecular Sciences
  12. Lean metabolic dysfunction-associated steatotic liver disease: Current insights and knowledge gaps
    Praveen Sandeep Raj R., Rebecca John, Felix Manoharan, Asisha M. Janeela, Ashish Goel, Nitin Kapoor · 2026 · Best Practice & Research Clinical Endocrinology & Metabolism
  13. Novel therapeutic strategies targeting mitochondrial quality control for metabolic dysfunction-associated steatotic liver disease
    Huiling Zuo, Jiaxin Chen, Yuhang Jiao, Xuan Ma, Xiangqiong Li, Yahui Xiao, Jiamei He, Zhuangzhuang Jia, Anhua Shi · 2026 · Frontiers in Physiology
  14. Nonalcoholic Fatty Liver Disease in Adults: The Impact of Diet and Other Therapeutic Interventions on Clinical and Histological Outcomes
    Madeline Erario, Zobair M. Younossi · 2013 · Springer eBooks
  15. Pathogenic Features of Insulin Resistance and Critical Organ Damage in the Liver, Muscle and Lung
    Kei Nakajima, Toshitaka Muneyuki, Masafumi Siato, Masafumi Kakei · 2011 · InTech eBooks
  16. Pharmacological and Non-Pharmacological Treatment in Non-Alcoholic Fatty Liver Disease
    Perdana Aditya Rahman, Rinaldi C. Lesmana · 2013 · The Indonesian Journal of Gastroenterology Hepatology and Digestive Endoscopy
  17. Olmesartan for non-alcoholic steatohepatitis complicated with hypertension: An open-label study
    Hisashi Hidaka, Makoto Ohbu, Yasuhiro Matsumoto, Tsutomu Minamino, Juichi Takada, Yoshiaki Tanaka, Yusuke Okuwaki, Masaaki Watanabe, Takahide Nakazawa, Akitaka Shibuya et al. · 2013 · Open Journal of Gastroenterology
  18. Enfermedad del hígado graso no alcohólico y riesgo cardiovascular
    Ángel Brea Hernando, José Puzo · 2010 · Clínica e Investigación en Arteriosclerosis
  19. Comparison of the effects of long-term pioglitazone and rosiglitazone therapy on liver enzymes in type 2 diabetes
    Phey Ming Yeap, Khalida Ann Lockman, Rob A. Elton, Margaret Boyd, Peter Clive Hayes, Alan J. Jaap · 2011 · The British Journal of Diabetes
  20. Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease
    Sang Hoon Park · 2014 · Korean Journal of Medicine
  21. Effect of Pioglitazone on Inflammatory and oxidative markers in patient with diabetic nephropathy
    Farahnoosh Farnood, Kamal Boostani, East Azerbaijan · 2014
  22. Current and emergent therapies in the non-alcoholic fatty liver
    Alfredo Arredondo Bruce, Jacqueline Amores Carraté, Gustavo Guerrero Mejías · 2010 · Revista Archivo Médico de Camagüey
  23. Long term effects of pioglitazone therapy with nonalcoholic steatohepatitis
    Haruo Nakayama, Shigetoshi Iwahasi, Toshiaki Ojima, Masao Kusano, Shigeyuki Asano, Yoshiki Sugai · 2009 · Kanzo
  24. Primary Prevention of Cardiovascular Disease with Collaborative Diabetes Study in the Efficacy of Statins: Meta-Analysis of Randomized Controlled Trials
    Hong Xiang Jiang, Hassah Batool Iftikhar · 2018 · Cardiology and Cardiovascular Medicine
  25. Comparative Efficacy of Saroglitazar and Pioglitazone in Nonalcoholic Fatty Liver Disease Patients: A Bayesian Network Meta-analysis
    Binayak Sinha, Samit Ghosal, Debasis Datta · 2024 · International Journal of Diabetes and Technology
  26. Unveiling the Multifaceted Role of CIDEB: From Apoptosis to Lipid Metabolism and Liver Health
    Louise Wutsdorff, Julienne Mougnekabol, Peter Tang, Anja Reutzel‐Selke, Igor Maximilian Sauer, Nils Haep · 2024 · Livers
  27. NASH – eine ungelöste therapeutische Herausforderung
    Ulrike Schempf, Ulrich M. Lauer, Michael Gregor, Michael Bitzer · 2010 · Die Gastroenterologie
  28. Non-Alcoholic Fatty Liver Disease (NAFLD): The Lipid Disease of the Liver and the Effect of Statins
    Mazen Noureddin, David Alexanian, Neil Kaplowitz · 2015 · Springer eBooks
  29. Review of current and potential future pharmacological treatments in nonalcoholic steatohepatitis
    Ahmed Akhter, Abhishek Pulla, Adnan Said · 2016 · Clinical Liver Disease
  30. Treatments of nonalcoholic fatty liver disease in adults who have no other illness: A Review article
    Sepideh Ahadi, Afshin Gharekhani, Afshin Shiva · 2019 · Arab Journal of Gastroenterology
  31. Hígado graso no alcohólico: certezas e incertidumbres de una epidemia silenciosa
    Esteban González Ballerga, Andrea Curia, Kenneth J. Cusi · 2020 · Acta gastroenteorológica latinoamericana/Acta gastroenterológica latinoamericana
  32. Portuguese Society for the Study of Obesity / Recommendations on Nutritional and Pharmacological Management of Diabetes After Bariatric Surgery
    Marta Alves, Carla A. Pedrosa, Cláudia Freitas, Gustavo Rocha, Isabel Albuquerque, João Duarte, Luı́s Cardoso, Raquel Carvalho, Sandra Belo, Teresa Azevedo et al. · 2019 · Revista Portuguesa de Endocrinologia Diabetes e Metabolismo
  33. Postgraduate Courses
    2009 · Scandinavian Journal of Gastroenterology
  34. The contribution of vascular adhesion protein-1 to glucose and lipid homeostasis in the liver
    Sumera Karim · 2013 · University of Birmingham Institutional Research Archive (University of Birmingham)
  35. Thiazolidinediones in NASH An Odd Couple Meant To Be?
    Kenneth J. Cusi · 2009 · Journal of Clinical Gastroenterology
  36. Effects of treatment of NAFLD on the metabolic syndrome
    Hannele Yki‐Järvinen · 2016
  37. Therapeutic Approaches for Nonalcoholic Steatohepatitis ( NASH )
    Ralf Glatthar, Robert H. Arch · 2021 · Burger's Medicinal Chemistry and Drug Discovery
  38. Manage non-alcoholic fatty liver disease using lifestyle interventions, as evidence for the use of pharmacological options is limited
    Adis Medical Writers · 2013 · Drugs & Therapy Perspectives
  39. Appropriateness of Statistics in Manuscript Reviews: A Decision Tree Approach
    Edward Lin · 2014 · Bariatric Surgical Practice and Patient Care
  40. Efeito anti-fibrogênico do doador de óxido nítrico S-nitroso-N-acetilcisteína (SNAC) na esteato-hepatite não alcóolica experimental
    Daniel Ferraz de Campos Mazo · 2012
  41. Uso de la técnica de perifusión de células hepáticas de rata en la investigación de las acciones metabólicas y mitocondriales directas de dos tiazolindionas, pioglitazona y rosiglitazona
    Maria de las Nieves Sanz García · 2010
  42. Nutritional modulation of hepatic lipid metabolism in health and disease
    Rich D. Johnston · 2012 · Nottingham ePrints (University of Nottingham)
  43. Drug Therapy for NASH: Insulin‐Sensitizing Agents (Metformin and Thiazolidinediones)
    Mohammad Shadab Siddiqui, Arun Jayant Sanyal · 2013
  44. A New Stereo Method Based On The Detector Of Local Structures
    Bogusław Cyganek, Jan Borgosz · 2002 · INFM-OAR (INFN Catania)
  45. Obesity and its Hepatic Complications in Adults and Children
    E. Jenny Heathcote, Eve A. Roberts · 2012
  46. The Chronic Liver Disease Patient
    Joanna K. Dowman, Philip Noel Newsome · 2011
  47. Insulin therapy in type 2 diabetes : Initiation, impact on liver fat, role of combination therapy with glitazones or glindes
    Leena Juurinen · 2014 · Työväentutkimus Vuosikirja
  48. Glucagon-like peptide-1 in nonalcoholic steatohepatitis
    Matthew James Armstrong · 2014 · University of Birmingham Institutional Research Archive (University of Birmingham)
  49. Thiazolidinediones for the Treatment of Nonalcoholic Steatohepatitis
    Atif Zaman · 2009 · Journal watch
  50. Сучасні підходи до лікування неалкогольної жирової хвороби печінки на фоні метаболічного синдрому
    K. A. Prosolenko · 2012
  51. OPINION Nonalcoholic fatty liver disease: new treatments
    T.L. Hardy, Quentin Mark Anstee, Christopher Paul Day · 2015
  52. Current and Emerging Therapies for Nonalcoholic Fatty Liver Disease
    Samer Gawrieh, Naga Chalasani · 2015 · Springer eBooks
  53. Can Pharmacologic Therapy Induce Histologic Improvement in Non-alcoholic Steatohepatitis?
    Nae‐Yun Heo · 2016 · Korean Journal of Gastroenterology
  54. Perspectives for managing of nonalcoholic fatty liver disease
    Pavel Koroy, Сляднев Сергей Александрович, Alexandr Yagoda · 2015 · Medical news of the North Caucasus
  55. What is the role of antifibrotic therapies in the current and future management of NAFLD?
    Natasha McDonald, Jonathan Andrew Fallowfield · 2016
  56. EDUCATION PRACTICE Abnormal Liver Tests and Fatty Liver on Ultrasound
    Stephen A. Harrison · 2008
  57. Metabolic Syndrome and the Liver
    Hitoshi Yoshiji · 2016 · Springer eBooks
  58. State-of-the-Art Lecture: Mechanisms of liver fibrosis — targets for therapy
    Timothy T. Gordon‐Walker, Antonella Pellicoro, John Peter Iredale · 2009 · Springer eBooks
  59. Non-alcoholic steatohepatitis — therapeutic interventions
    Chris Day · 2009 · Springer eBooks
  60. Deregulation of fatty acid metabolism and cannabinoid receptors in liver of morbidly obese women with non-alcoholic fatty liver disease
    Alba Berlanga · 2015 · TDX (Tesis Doctorals en Xarxa)
  61. Revisión de los tratamientos farmacológicos actuales y futuros de la esteatohepatitis no alcohólica
    Ahmed Akhter, Abhishek Pulla, Adnan Said · 2016 · Clinical Liver Disease
  62. Chronic hepatitis
    Christopher D. Anderson, Jeffrey S. Crippin · 2012 · Elsevier eBooks
  63. 1) Reversibility and Treatment of Liver Fibrosis
    Yutaka Inagaki, Hideaki Sumiyoshi · 2014 · Nihon Naika Gakkai Zasshi
  64. Chronic hepatitis
    Christopher D. Anderson, Jeffrey S. Crippin · 2017 · Elsevier eBooks
  65. Pioglitazone versus metformin in Egyptian non diabetic patients with Non Alcholic Fatty Liver Disease: A randomized controlled trial.
    Sahar K. Hgazy, Mamdouh Ahmed Gabr, Nahla E. El‐Ashmawy, Maha A. Younis · 2017 · IOSR Journal of Pharmacy (IOSRPHR)
  66. Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes
    Kenneth J. Cusi · 2017 · Contemporary diabetes
  67. Symposium 5 (Joint Nutrition Society and BAPEN Symposium): Too many pies: metabolic competencies in obesity The importance of fatty liver disease in clinical practice
    Jeremy Cobbold, Quentin Mark Anstee, Simon David Taylor-Robinson · 2010
  68. Affect of late-onset prenatal care on antenatal diagnosis.
    Joann Norma Bodurtha, L Corey, Walter E. Nance · 1986 · PubMed
  69. Efficacy of ursodezoxycolic acid in the treatment of non-alcoholic fatty liver disease
    Diana T. Dicheva, Е. И. Кузнецова, T. A. Baeva · 2018 · Meditsinskiy sovet = Medical Council
  70. Treatment of Recurrent Nonviral Disease
    James Neuberger · 2012 · Elsevier eBooks
  71. Combination of synbiotic and sitagliptin in nonalcoholic fatty liver disease: Is it better than sitagliptin alone?
    Yong Kyun Cho · 2018 · Clinical and Molecular Hepatology
  72. New pharmacological approaches in type 2 diabetes mellitus
    Kenneth J. Cusi · 2009 · Dialnet (Universidad de la Rioja)
  73. Examination of the scientific evidences for off-label use of medications in non-alcoholic fatty liver disease
    Gabriela Correia Matos de Oliveira, Gustavo Magno Baptista, Elizabel Izidorio Lima, Alcina Maria Vinhaes Bittencourt, Luís Jesuino De Oliveira Andrade · 2019 · Revista de Ciências Médicas e Biológicas
  74. Bariatric Surgery and NASH: A Feasible Option
    Lidia Castagneto‐Gissey, James R. Casella-Mariolo, Geltrude Mingrone · 2020 · Springer eBooks
  75. Pharmacological Options for NASH
    Christiane Stern, Vlad Ratziu · 2020 · Springer eBooks
  76. Non-Alcoholic Fatty Liver Disease
    Jung Hwan Kim · 2014
  77. Ruolo dei farmaci antidiabete nel trattamento della NAFLD
    Alessandro Mantovani · 2021 · il Diabete
  78. Impact of statin treatment on non-invasive tests based prediction of fibrosis
    Mustafa Al‐Karaghouli · 2021 · ERA: Education and Research Archive (University of Alberta)
  79. Gyrate Atrophy, High myopia, Night blindness, Ornithine Aminotransferase, Posterior sub capsular cataract.
    G Satyavathi, Y Srinivas, Malleswari · 2015
  80. Viral alcoholic and fatty liver diseases
    Ehud Zigmond, Daniel Shouval · 2021
  81. Current World Literature
    2009 · Current Opinion in Endocrinology Diabetes and Obesity
  82. Current World Literature
    2009 · Current Opinion in Lipidology
  83. Adipose tissue
    Da Young Lee, Tuy An Trinh, Myoung‐Sook Shin, Ki Sung Kang · 2022 · Elsevier eBooks
  84. Insights into Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis
    Gabriel Scarlat, Bassil Dona, Mihai Cârstea, Marilena Stoian · 2022 · Internal Medicine
  85. N
    2012 · Elsevier eBooks
  86. Therapeutic Potential of Green Coffee Bean in Nonalcoholic Fatty Liver Disease
    Debasis Bagchi, Hiroyoshi Moriyama, Anand Swaroop · 2016 · CRC Press eBooks
  87. News from the FAL
    2011 · Alternatives to Laboratory Animals
  88. Foie métabolique
    Maud Lemoine, Lawrence Serfaty · 2011 · EMC - Hépatologie
  89. Drugs and Mechanisms Related to the Treatment of Nonalcoholic Fatty Liver Disease
    钊 牟 · 2021 · Advances in Clinical Medicine
  90. 2. Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalchoholic Steatohepatitis (NASH)
    Saburo Ohnishi, Toshiharu Saibara · 2009 · Nihon Naika Gakkai Zasshi
  91. Genetically-proxied anti-diabetic drug target perturbation and risk of cancer: a Mendelian randomization analysis
    James Yarmolinsky, Emmanouil Bouras, Andrei‐Emil Constantinescu, Kimberley Burrows, Caroline J. Bull, Emma E. Vincent, Richard Michael Martin, Olympia Dimopoulou, Sarah Jane Lewis, Victor Rau Moreno et al. · 2022 · medRxiv
  92. Non-alcoholic Steatohepatitis Diagnosis and Treatment Medical and Surgery, Based on Guideline Updates: A Mini Review
    Mohsen Arabi, Raheleh Alimoradzadeh, Alireza Makian, Seyed Abbas Nabavi, Farshad Divsalar, Mitra Kazemi Jahromi · 2022 · Journal of Health Reports and Technology
  93. Effect of Canagliflozin on liver steatosis in obese non diabetic patients with non-alcoholicfatty liver disease: A double blind randomized controlled trial
    Borwonkhun Tontivuthikul, Witthawat Naeowong, Weerapan Khovidhunkit · 2019
  94. Correlação entre parâmetros antropométricos e a ocorrência de doença hepática gordurosa não-alcoólica em indivíduos obesos submetidos à cirurgia bariátrica
    Silênio Souza Reis · 2021
  95. Associação entra a doença hepática gordurosa não alcoólica e o adenocarcinoma ductal de pâncreas
    Achiles Queiroz Monteiro de Rezende · 2021
  96. Pharmacologic therapies in metabolic syndrome with special reference to non-alcoholic fatty liver disease
    Arun Jayant Sanyal, Mark Dhinesh Muthiah, Eunice Xiang Xuan Tan · 2024 · Elsevier eBooks
  97. Community Series - Liver Fibrosis and MAFLD: from Molecular Aspects to Novel Pharmacological Strategies, Volume II
    2024 · Frontiers research topics
  98. MANAGEMENT OF NON-ALCOHOLIC HEPATIC STEATOSIS: WHAT’S NEW?
    Júlia Smaniotto Ritt, Luísa Barbiero Dutra, LUIZA MEZOMO CANTARELLI, BRUNO RAFAEL MABONI ROTH, ISADORA CORRÊA PROVENSI, LUIZA FENALTE STREHER, Michel Kovalski Batista, MÉLLANY ABREU DA COSTA, Ana Carolina Risson, Bruno da Silva Riterbusche et al. · 2024 · International Journal of Health Science
  99. MASLD- Global prevalence, pathophysiological processes and management pathways- tackling a complex problem
    Gourdas Choudhuri, Seema R Kalel, Zubin Dev Sharma, Rinkesh Bansal · 2024 · Gastroenterology & Hepatology Open Access
  100. PPARγ regulates PNPLA3 in adipocytes in vitro and in vivo in healthy obese patients and mice with metabolic dysfunction-associated steatohepatitis
    Emmanuel Dauda Dixon, Thierry Claudel, Ursula A. White, Robert Zimmermann, Guenter Haemmerle, Martin Wabitsch, Veronika Mlitz, Claudia D. Fuchs-Steiner, Éric Ravussin, Michael A Trauner · 2024 · Research Square